We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Edwards' Q3 Earnings on the Horizon: What's in the Cards?
Read MoreHide Full Article
Key Takeaways
Edwards expects Q3 revenues of $1.68 billion and EPS of 73 cents, up 8% and 9%, respectively.
EW's TAVR revenues are projected to grow 35%, driven by SAPIEN demand and expanded patient access.
EW's TMTT and Surgical revenues are expected to rise 5.1% and 3.5%, supported by product adoption.
Edwards Lifesciences Corp. (EW - Free Report) is scheduled to report third-quarter 2026 results on Nov. 4, after the market closes.
In the last reported quarter, the company’s adjusted earnings per share (EPS) of 78 cents beat the Zacks Consensus Estimate by 6.85%. Its earnings topped estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 4.49%.
Edwards' Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.68 billion, suggesting 8% growth from the year-ago reported figure.
The Zacks Consensus Estimate for net earnings of 73 cents per share indicates a 9% increase from the year-ago reported figure. The estimate has remained unchanged in the past 60 days.
Factors Likely to Influence EW’s Q3 Results
Transcatheter Aortic Valve Replacement (“TAVR”)
In the third quarter of 2026, the TAVR segment is likely to have maintained its momentum, aided by procedural growth amid a heightened clinical focus on proactive disease management of severe aortic stenosis. Long-term clinical evidence supporting the SAPIEN platform’s durability and valve performance may have been a key driver.
Edwards likely continued to witness strong sales of its SAPIEN 3 Ultra RESILIA valve in the United States and international markets, including Japan. It also received the asymptomatic indication approval in Japan. In Europe, continued commercial execution and sustained physician demand for the SAPIEN platform are expected to have supported its performance. The company likely continued to benefit from the exit of a competitor in the prior year.
In September, EW welcomed CMS’ updated National Coverage Determination (“NCD”) for TAVR, stating that the policy is expected to expand patient access, streamline care and provide greater flexibility to multidisciplinary Heart Teams in evaluating and treating patients with aortic stenosis.
The Zacks Consensus Estimate for TAVR revenues implies growth of 35% year over year in the third quarter.
Transcatheter Mitral and Tricuspid Therapies (“TMTT”)
Within TMTT, Edwards’ ongoing strength in the portfolio of repair and replacement therapies to treat mitral and tricuspid diseases is expected to have resulted in solid top-line growth. The EVOQUE tricuspid valve replacement system is likely to have continued to gain traction in both the United States and Europe. Demand for the PASCAL transcatheter edge-to-edge repair system may have continued to expand, driven by physician interest in its differentiated design and clinical outcomes, as well as the significant unmet need among these patients.
Last year, the FDA approval of the SAPIEN M3 mitral valve replacement system marked a major milestone as the first transcatheter therapy utilizing a transseptal approach. Edwards’ early commercial experience has reflected the need for this mitral replacement solution for patients for whom mitral TEER is not an appropriate treatment option.
Edwards Lifesciences Corporation Price and EPS Surprise
In the previous quarter, Edwards received the CE Mark for SAPIEN M3 RESILIA and expanded the indications for both SAPIEN M3 and SAPIEN M3 RESILIA to include patients with mitral annular calcification (MAC), broadening access to treatment for a patient population with significant unmet medical needs. We expect the development to have boosted third-quarter top-line growth.
The Zacks Consensus Estimate for TMTT revenues calls for an increase of 5.1% year over year in third-quarter 2026.
Surgical Structural Heart
The segment’s third-quarter performance is likely to have benefited from the continued demand for Edwards’ RESILIA therapies - INSPIRIS, MITRIS and KONECT. The global adoption of the INSPIRIS aortic valve is expected to have remained strong, while the KONECT tissue valved conduit must have continued to gain traction. The rollout of the MITRIS valve across more international markets may have supported growth in surgical mitral valve replacement procedures.
The Zacks Consensus Estimate for Surgical revenues indicates growth of 3.5% year over year.
Earnings Whispers for Edwards
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is exactly the case here, as you can see below:
Earnings ESP: Edwards has an Earnings ESP of +0.76%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some other medical stocks worth considering, as these, too, have the right combination of elements to post an earnings beat this time around:
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed in the other three, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity (RVTY - Free Report) has an Earnings ESP of +1.03% and a Zacks Rank #3 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
Acadia Healthcare (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4.
ACHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter’s figure.
View the Zacks #1 Rank List
Image: Bigstock
Edwards' Q3 Earnings on the Horizon: What's in the Cards?
Key Takeaways
Edwards Lifesciences Corp. (EW - Free Report) is scheduled to report third-quarter 2026 results on Nov. 4, after the market closes.
In the last reported quarter, the company’s adjusted earnings per share (EPS) of 78 cents beat the Zacks Consensus Estimate by 6.85%. Its earnings topped estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 4.49%.
Edwards' Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.68 billion, suggesting 8% growth from the year-ago reported figure.
The Zacks Consensus Estimate for net earnings of 73 cents per share indicates a 9% increase from the year-ago reported figure. The estimate has remained unchanged in the past 60 days.
Factors Likely to Influence EW’s Q3 Results
Transcatheter Aortic Valve Replacement (“TAVR”)
In the third quarter of 2026, the TAVR segment is likely to have maintained its momentum, aided by procedural growth amid a heightened clinical focus on proactive disease management of severe aortic stenosis. Long-term clinical evidence supporting the SAPIEN platform’s durability and valve performance may have been a key driver.
Edwards likely continued to witness strong sales of its SAPIEN 3 Ultra RESILIA valve in the United States and international markets, including Japan. It also received the asymptomatic indication approval in Japan. In Europe, continued commercial execution and sustained physician demand for the SAPIEN platform are expected to have supported its performance. The company likely continued to benefit from the exit of a competitor in the prior year.
In September, EW welcomed CMS’ updated National Coverage Determination (“NCD”) for TAVR, stating that the policy is expected to expand patient access, streamline care and provide greater flexibility to multidisciplinary Heart Teams in evaluating and treating patients with aortic stenosis.
The Zacks Consensus Estimate for TAVR revenues implies growth of 35% year over year in the third quarter.
Transcatheter Mitral and Tricuspid Therapies (“TMTT”)
Within TMTT, Edwards’ ongoing strength in the portfolio of repair and replacement therapies to treat mitral and tricuspid diseases is expected to have resulted in solid top-line growth. The EVOQUE tricuspid valve replacement system is likely to have continued to gain traction in both the United States and Europe. Demand for the PASCAL transcatheter edge-to-edge repair system may have continued to expand, driven by physician interest in its differentiated design and clinical outcomes, as well as the significant unmet need among these patients.
Last year, the FDA approval of the SAPIEN M3 mitral valve replacement system marked a major milestone as the first transcatheter therapy utilizing a transseptal approach. Edwards’ early commercial experience has reflected the need for this mitral replacement solution for patients for whom mitral TEER is not an appropriate treatment option.
Edwards Lifesciences Corporation Price and EPS Surprise
Edwards Lifesciences Corporation price-eps-surprise | Edwards Lifesciences Corporation Quote
In the previous quarter, Edwards received the CE Mark for SAPIEN M3 RESILIA and expanded the indications for both SAPIEN M3 and SAPIEN M3 RESILIA to include patients with mitral annular calcification (MAC), broadening access to treatment for a patient population with significant unmet medical needs. We expect the development to have boosted third-quarter top-line growth.
The Zacks Consensus Estimate for TMTT revenues calls for an increase of 5.1% year over year in third-quarter 2026.
Surgical Structural Heart
The segment’s third-quarter performance is likely to have benefited from the continued demand for Edwards’ RESILIA therapies - INSPIRIS, MITRIS and KONECT. The global adoption of the INSPIRIS aortic valve is expected to have remained strong, while the KONECT tissue valved conduit must have continued to gain traction. The rollout of the MITRIS valve across more international markets may have supported growth in surgical mitral valve replacement procedures.
The Zacks Consensus Estimate for Surgical revenues indicates growth of 3.5% year over year.
Earnings Whispers for Edwards
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is exactly the case here, as you can see below:
Earnings ESP: Edwards has an Earnings ESP of +0.76%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other MedTech Picks
Here are some other medical stocks worth considering, as these, too, have the right combination of elements to post an earnings beat this time around:
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed in the other three, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity (RVTY - Free Report) has an Earnings ESP of +1.03% and a Zacks Rank #3 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
Acadia Healthcare (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4.
ACHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter’s figure.